AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 251 min read$OMER

Borges David J. sold $419K of OMER

Borges David J. (VP, Finance & CAO) sold 20,000 shares of OMEROS CORP (OMER) at $20.95 ($0.42M total) across 2 trades over 2026-09-22 to 2026-09-23 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Borges David J.
Published Sep 25, 2026, 1:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 1:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$OMER
Bearish
medium confidence
Mentioned
$OMER
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMERBearishLow
01

Why it matters

The complete divestiture by a senior finance officer may prompt short‑term scrutiny but is unlikely to move the broader market.

02

Market read

Relevant primarily to OMER shareholders; minimal broader market impact.

03

What to watch

The 10b5‑1 plan pre‑arranged; insider may have had tax or liquidity motives.

Relevance 3/10Novelty 4/10Timing: filed 2026-09-24, effective immediately

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

$OMERBearishMedium confidence
Context

VP of Finance sold 20,000 shares for $419K via a 10b5‑1 plan, leaving zero holdings.

Expected impact

Potential short‑term dip of 1‑2% as market digests the sale.

Evidence & confidence

Sale size is modest relative to market cap, but complete exit by a senior officer can weigh on sentiment.

Market effects

Sector

None beyond OMER; sector unchanged.

Regional

No regional effect.

Global

Limited to OMER shareholders.

Counterpoint

What could challenge this read

Sale could be purely portfolio rebalancing, not a negative signal.

Key entities

  • Officer
    Borges David J.

    VP, Finance & CAO of OMEROS Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

OMER insider trading history →

Related articles

OCT 19
$AZNMedAI 8/10

CHMP October decisions: AstraZeneca pulls prostate cancer filing; Orphelia gets a second chance; Ascendis nears EU launch

AstraZeneca withdrew its EU application for Truqap in prostate cancer. Orphelia Pharma gained CHMP backing for Kizfizo in glioblastoma. Ascendis Pharma neared EU approval for Yuviwel in achondroplasia. Sobi expanded Tryngolza's use to severe hypertriglyceridemia. Pfizer withdrew Ibrance's EU expansion. Revolution Medicines got CHMP backing for Rasonque in pancreatic cancer. Omeros failed to overturn Yartemlea's EU rejection. Lilly advanced Foundayo for obesity and diabetes in Europe.

european-biotechnology.com3 min
OCT 16
$OMERHighAI 8/10

Why is Omeros stock sliding today?

Omeros (OMER) stock fell 5.4% in pre-market trading after the European Medicines Agency's committee issued a second negative opinion on its Yartemlea drug application. The company will end its European compassionate-use program and abandon plans to license EU commercialization rights. Insiders sold $3M in shares over the past year. The stock traded at $17.77, down from $18.79. The U.S. launch of Yartemlea remains on track, with next earnings expected in mid-November.

investing.com2 min